space between

Articles

Teva is looking to evolve its business through new R&D programmes and development of 'New Therapeutic Entities' from off-patent drugs.

Oncology

Dr Li Mao and Dr Giovanni Selvaggi of Betta Pharmaceuticals and Xcovery Holdings discuss their novel ALK inhibitor and the Chinese biotech landscape.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.